DiMe and Partners Align on Digital Atopic Dermatitis Endpoint

DiMe's release of a new set of resources to advance the use of digitally measured nocturnal scratch as a meaningful endpoint for atopic dermatitis (AD) was completed with founding project partners AbbVie, the Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis, Pfizer, and UCB, along with project collaborators Advancing Innovation in Dermatology, Almirall, Eli Lilly, GSK, Leo Pharma, and Sanofi. In just nine months, the collaboration conducted a mixed-methods study, a comprehensive literature review, a series of workshops, a series of focus groups with payers, and convened a meeting with regulators - all of which informed the development of these open-access resources.

Read the full press release.